Mainz Biomed's Participation in MEDICA 2025
Mainz Biomed N.V. (NASDAQ: MYNZ) is excited to share its involvement in MEDICA 2025, a premier global healthcare exhibition. This significant event is expected to draw a diverse community of over 5,000 exhibitors and 80,000 visitors from different countries, providing an unparalleled platform for industry advancements, communication, and networking.
Innovative Solutions for Cancer Detection
As a leading molecular genetics diagnostic company, Mainz Biomed focuses on early cancer detection. During MEDICA 2025, the Company will spotlight its flagship product, ColoAlert®, an innovative stool-based screening test designed for the early detection of colorectal cancer. This non-invasive test enables easier access and encourages more individuals to participate in screening.
In addition to ColoAlert®, Mainz Biomed aims to unveil future diagnostic innovations that contribute to early-stage cancer diagnosis. This participation underscores the Company's commitment to improving cancer prevention methodologies and enhancing patient outcomes through advanced medical solutions.
Networking and Collaboration Opportunities
MEDICA 2025 offers an excellent opportunity for professionals in the healthcare sector to connect. With a series of high-level forums, discussions, and special exhibitions, attendees can engage with industry leaders, policymakers, and healthcare professionals. This environment fosters valuable exchanges of ideas and encourages collaborations aimed at shaping the future of cancer diagnostics.
Mainz Biomed invites attendees to visit their booth at the Rhineland-Pfalz pavilion, located in Hall 3, E92. Here, they will showcase their advancements and engage with individuals who share a passion for transforming cancer detection.
About Mainz Biomed N.V.
Mainz Biomed is dedicated to developing effective, market-ready molecular genetic diagnostic solutions tailored for serious health issues. The Company's standout product, ColoAlert®, is gaining traction across Europe as a reliable tool for colorectal cancer screening. Furthermore, Mainz Biomed is conducting the eAArly DETECT 2 clinical study to lay the groundwork for potential FDA approval in the US, signifying its commitment to expanding its impact in the cancer detection field.
Additionally, the Company's portfolio includes PancAlert, an early-stage screening test for pancreatic cancer, utilizing real-time Polymerase Chain Reaction (PCR) technology to detect molecular-genetic markers in blood and stool samples.
Contact Information
For media inquiries, reach out to MC Services AG: Maximilian Schur / Simone Neeten +49 211 529252 20 mainzbiomed@mc-services.eu
For investor inquiries, please contact ir@mainzbiomed.com.
Frequently Asked Questions
What is MEDICA 2025?
MEDICA 2025 is a prominent international healthcare trade fair that showcases innovations, products, and services in the medical sector.
What products will Mainz Biomed showcase at MEDICA 2025?
Mainz Biomed will highlight its flagship product, ColoAlert®, an early detection tool for colorectal cancer, along with upcoming diagnostic solutions.
What is the purpose of ColoAlert®?
ColoAlert® is designed to facilitate early detection of colorectal cancer through a non-invasive stool test, making screening more accessible for patients.
How can professionals network at MEDICA 2025?
Attendees can participate in forums and exhibitions, connecting with industry leaders and exploring collaborative opportunities in cancer diagnostics.
Where can I learn more about Mainz Biomed?
For detailed information, visit Mainz Biomed’s official website or follow them on social media platforms for updates.